Staphylococcus Biology in Ocular Infections

眼部感染中的葡萄球菌生物学

基本信息

项目摘要

PROJECT SUMMARY / ABSTRACT Bacterial eye infections cause a significant number of cases of blindness worldwide. Staphylococcus aureus causes a majority of these infections of the cornea (keratitis) and interior of the eye (endophthal- mitis). S. aureus produces several adhesins on its surface which aid in tissue attachment, surface components which trigger innate immune pathways and inflammation, and toxins which disrupt barriers and kill immune cells. The coordinated synthesis of these virulence factors aids the organism in host survival, and the host is usually negatively affected. In the eye, this can manifest as a painfully damaged cornea or irreversibly damaged retina, resulting in significant vision loss. To make matters worse, S. aureus is considered a Serious Threat on the CDC’s list of Antibiotic Resistance Threats in the US. MRSA and multidrug resistance are now common in ocular isolates, elevating the risk of ocular infections that are difficult to treat. We and others have investigated the pathogenic mechanisms underlying ocular bacterial infections. For S. aureus, animal infection models and ocular cell lines have been used to investigate the areas noted above. We have a very good idea of which toxins damage the cornea and retina and which innate pathways are involved in corneal and intraocular inflammation. This proposal is focused on the factors involved in the earliest events in S. aureus ocular infections, events that, to date, have drawn minimal attention. This new R01 proposal is based on the global hypothesis that coordinated regulation of S. aureus adhesins and toxins facilitate adherence to tissue, barrier breach, and escape from the acute immune response. The scientific premise is based on preliminary and published data demonstrating that: 1) adhesins on the S. aureus surface, when absent, reduce adhesion to corneal cells, 2) leukotoxins, when absent, reduce virulence in keratitis and endophthalmitis, and 3) S. aureus breach of the blood-retina barrier appears to be adhesin- and toxin-mediated. These areas are investigated in three separate but related aims focused on early events in S. aureus keratitis and endophthalmitis. We will use well-characterized S. aureus virulence factor- defective mutants and feasible in vitro and in vivo infection models in rigorous and straightforward experiments designed to define the S. aureus factors important in these events. For patients with eye infections, ineffective treatment often equates with vision loss. Our approaches to addressing these gaps in our field are innovative, translationally relevant, and will move the ocular infectious disease field forward by identifying the S. aureus factors responsible for adhesion to tissue and circumvention of the acute response, possibly uncovering targets that lead to more rational use or development of therapeutics for prevention and treatment of infection. These studies are a logical extension of our ocular infection research program, and we are well positioned to contribute new and important information that will improve options for preventing infection and preserving vision.
项目总结/摘要 细菌性眼部感染在全世界范围内导致大量失明病例。葡萄球菌 金黄色葡萄球菌引起大多数角膜(角膜炎)和眼内(眼内炎, 缓解)。S.金黄色葡萄球菌在其表面上产生几种粘附素,这些粘附素有助于组织附着、表面成分 引发先天免疫途径和炎症,以及破坏屏障和杀死免疫系统的毒素。 细胞这些毒力因子的协调合成有助于生物体在宿主中存活,并且宿主是 通常受到负面影响。在眼睛里,这可能表现为角膜的痛苦损伤或不可逆转的 视网膜受损,导致严重视力丧失。更糟糕的是,S。金黄色葡萄球菌被认为是严重 疾病控制和预防中心的抗生素耐药性威胁在美国的名单上的威胁。MRSA和多药耐药性现在 常见于眼部分离株,增加了难以治疗的眼部感染的风险。 我们和其他人已经研究了眼部细菌感染的致病机制。为 S.金黄色葡萄球菌、动物感染模型和眼细胞系已用于研究上述领域。 我们对哪些毒素损害角膜和视网膜以及哪些先天途径 与角膜和眼内炎症有关。本建议的重点是涉及的因素, 最早的事件在S。金黄色葡萄球菌眼部感染,迄今为止,这些事件引起的关注最少。 这个新的R 01建议是基于全局假设,即协调调节S。金黄色 粘附素和毒素有助于粘附于组织,破坏屏障,并逃避急性免疫反应。 反应科学前提是基于初步和已发表的数据,表明:1)粘附素 在S.金黄色葡萄球菌表面,当不存在时,减少与角膜细胞的粘附,2)白细胞毒素,当不存在时,减少 角膜炎和眼内炎的毒力;金黄色葡萄球菌对血视网膜屏障的破坏似乎是 粘附素和毒素介导的。这些领域的调查在三个独立的,但相关的目标集中在早期 事件在S。金黄色角膜炎和眼内炎。我们将使用特征良好的S。金黄色葡萄球菌毒力因子- 缺陷突变体和可行的体外和体内感染模型,在严格和直接的实验 旨在定义S.金黄色葡萄球菌因素在这些事件中很重要。 对于眼部感染的患者,无效的治疗往往等同于视力丧失。我们的方法 在我们的领域解决这些差距是创新的,相关的,并将移动眼部感染 通过对S.金黄色葡萄球菌因子负责粘附到组织和规避 急性反应,可能会发现导致更合理使用或发展的目标, 用于预防和治疗感染的治疗剂。这些研究是我们视觉的逻辑延伸, 感染研究计划,我们有能力提供新的重要信息, 改善预防感染和保护视力的选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michelle C Callegan其他文献

Michelle C Callegan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michelle C Callegan', 18)}}的其他基金

Staphylococcus Biology in Ocular Infections
眼部感染中的葡萄球菌生物学
  • 批准号:
    10672933
  • 财政年份:
    2021
  • 资助金额:
    $ 35.16万
  • 项目类别:
Staphylococcus Biology in Ocular Infections
眼部感染中的葡萄球菌生物学
  • 批准号:
    10296009
  • 财政年份:
    2021
  • 资助金额:
    $ 35.16万
  • 项目类别:
Phage-Based Therapeutics for Ocular Infections
基于噬菌体的眼部感染治疗
  • 批准号:
    10219273
  • 财政年份:
    2020
  • 资助金额:
    $ 35.16万
  • 项目类别:
Phage-Based Therapeutics for Ocular Infections
基于噬菌体的眼部感染治疗
  • 批准号:
    10039252
  • 财政年份:
    2020
  • 资助金额:
    $ 35.16万
  • 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
  • 批准号:
    10178032
  • 财政年份:
    2018
  • 资助金额:
    $ 35.16万
  • 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
  • 批准号:
    9759927
  • 财政年份:
    2018
  • 资助金额:
    $ 35.16万
  • 项目类别:
Pathogenic Mechanisms of Bacillus Endophthalmitis
芽孢杆菌眼内炎的致病机制
  • 批准号:
    10428514
  • 财政年份:
    2018
  • 资助金额:
    $ 35.16万
  • 项目类别:
Nanotherapeutics for Ocular Infections
眼部感染的纳米疗法
  • 批准号:
    8985810
  • 财政年份:
    2015
  • 资助金额:
    $ 35.16万
  • 项目类别:
Nanotherapeutics for Ocular Infections
眼部感染的纳米疗法
  • 批准号:
    9341333
  • 财政年份:
    2015
  • 资助金额:
    $ 35.16万
  • 项目类别:
Vision Science Training Program
视觉科学培训计划
  • 批准号:
    10180599
  • 财政年份:
    2014
  • 资助金额:
    $ 35.16万
  • 项目类别:

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 35.16万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 35.16万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 35.16万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 35.16万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 35.16万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 35.16万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 35.16万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 35.16万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 35.16万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 35.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了